Market Currents
Cyclacel Pharmaceuticals (CYCC +40.4%) soars after saying that Phase II studies of it's lead...
-
Monday, October 15, 2012, 12:15 PM ETCyclacel Pharmaceuticals (CYCC +40.4%) soars after saying that Phase II studies of it's lead drug candidate Sapacitabine, a treatment for older patients with intermediate-2 or high-risk myelodysplastic syndrome, nearly doubled expected survival rates for elderly patients.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
